https://www.socictopen.socict.org/files/original/c086aa69ea9602172f9c33cb7cbb0a49.pdf e3fe558d96e13bc07f94c58bd48a3d89 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Cancer and SARS-CoV-2 Infection: Diagnostic and Therapeutic Challenges. Creator An entity primarily responsible for making the resource Sebastiano Gangemi, Caterina Musolino, Giovanni Pioggia, Alessandro Allegra, Alessandro Tonacci Description An account of the resource In late December 2019, a new infectious viral disease appeared. A new betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has been recognized as the pathogen responsible for this infection. Patients affected by tumors are more vulnerable to infection owing to poor health status, concomitant chronic diseases, and immunosuppressive conditions provoked by both the cancer and antitumor therapies. In this review, we have analyzed some lesser known aspects of the relationship between neoplasms and SARS-CoV-2 infection, starting from the different expression of the ACE2 receptor of the virus in the various neoplastic pathologies, and the roles that different cytokine patterns could have in vulnerability to infection and the appearance of complications. This review also reports the rationale for a possible use of drugs commonly employed in neoplastic therapy, such as bevacizumab, ibrutinib, selinexor, thalidomide, carfilzomib, and PD-1 inhibitors, for the treatment of SARS-CoV-2 infection. Finally, we have highlighted some diagnostic challenges in the recognition of SARS-CoV-2 infection in cancer-infected patients. The combination of these two health problems-tumors and a pandemic virus-could become a catastrophe if not correctly handled. Careful and judicious management of cancer patients with SARS-Cov-2 could support a better outcome for these patients during the current pandemic. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource Epidemiology, cancer, treatment, immunosuppression, cytokines, Prognosis, risk factor, SARS-CoV-2, COVID-19 Identifier An unambiguous reference to the resource within a given context DOI: 10.3390/cancers12061581 Source A related resource from which the described resource is derived Cancers Publisher An entity responsible for making the resource available MDPI AG